AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18472409 — intervention group
Group type: COMPARATOR
Intervention: No dietary intervention (n=231)
Number of subjects: 563
Study 18472409 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Number of subjects: 563
Study 17413100 — intervention group
Group type: EXPERIMENTAL
Intervention: MUFA diet (n = 12)
Number of subjects: 27
Study 17413100 — intervention group
Group type: COMPARATOR
Intervention: LF diet (n = 15)
Number of subjects: 27
Study 16732144 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisolone (2 mg/kg per day in three divided doses for 3 days)
Number of subjects: 78
Study 16732144 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 12600864 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed tocopherols
Number of subjects: 46
Study 12600864 — intervention group
Group type: COMPARATOR
Intervention: Alpha‐tocopherol
Number of subjects: 46
Study 12600864 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 46
Study 10343208 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 198
Study 10343208 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 198
Study 8955466 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin-to-skin with father
Number of subjects: 44
Study 8955466 — intervention group
Group type: COMPARATOR
Intervention: Cot
Number of subjects: 44
Study 8955466 — intervention group
Group type: COMPARATOR
Intervention: Incubator
Number of subjects: 44
Study 1834443 — intervention group
Group type: EXPERIMENTAL
Intervention: Insufflatable abdominal girdle (IAG)
Number of subjects: 160
Study 1834443 — intervention group
Group type: COMPARATOR
Intervention: Control group (no IAG)
Number of subjects: 160
Study 6179975 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-blind food challenge (DBFC)
Number of subjects: 22
Study 6179975 — intervention group
Group type: COMPARATOR
Intervention: Skin test
Number of subjects: 22
Study 6179975 — intervention group
Group type: COMPARATOR
Intervention: Leukocyte histamine release (LHR)
Number of subjects: 22
Study 6179975 — intervention group
Group type: COMPARATOR
Intervention: RAST
Number of subjects: 22
Study 31256328 — intervention group
Group type: EXPERIMENTAL
Intervention: Pink Pad®
Number of subjects: 60
Study 31256328 — intervention group
Group type: COMPARATOR
Intervention: egg‐crate foam
Number of subjects: 60
Study 30593173 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical acupoint stimulation (TEAS)
Number of subjects: 53
Study 30593173 — intervention group
Group type: COMPARATOR
Intervention: Control group (group C)
Number of subjects: 53
Study 27103222 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIT)
Number of subjects: 18
Study 27103222 — intervention group
Group type: COMPARATOR
Intervention: Moderate-Intensity Continuous Training (MCT)
Number of subjects: 18
Study 24005332 — intervention group
Group type: EXPERIMENTAL
Intervention: EZLoc femoral fixation device
Number of subjects: 110
Study 24005332 — intervention group
Group type: COMPARATOR
Intervention: Bone Mulch Screw
Number of subjects: 110
Study 20720484 — intervention group
Group type: EXPERIMENTAL
Intervention: Heptaminol hydrochloride
Number of subjects: 49
Study 20629576 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternate vaccination schedule at 0, 2, and 12 months
Number of subjects: 200
Study 20629576 — intervention group
Group type: COMPARATOR
Intervention: Standard vaccination schedule at 0, 2, and 6 months
Number of subjects: 200
Study 18780503 — intervention group
Group type: EXPERIMENTAL
Intervention: Penehyclidine hydrochloride (0.01 mg/kg)
Number of subjects: 120
Study 18780503 — intervention group
Group type: COMPARATOR
Intervention: Atropine (0.01 mg/kg)
Number of subjects: 120
Study 18780503 — intervention group
Group type: COMPARATOR
Intervention: Scopolamine (0.006 mg/kg)
Number of subjects: 120
Study 16038528 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam + chemotherapy
Number of subjects: 45
Study 16038528 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol + chemotherapy
Number of subjects: 45
Study 16038528 — intervention group
Group type: COMPARATOR
Intervention: Control (chemotherapy only)
Number of subjects: 45
Study 16038528 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam + chemotherapy and Propofol + chemotherapy
Number of subjects: 45
Study 12518498 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan/pyrophosphate dentifrice
Number of subjects: 0
Study 12518498 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan/copolymer dentifrice
Number of subjects: 0
Study 12518498 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan placebo dentifrice
Number of subjects: 0
Study 12518498 — intervention group
Group type: COMPARATOR
Intervention: Sodium fluoride control (NaF) dentifrice
Number of subjects: 0
Study 10527293 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole test
Number of subjects: 43
Study 10527293 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 7724308 — intervention group
Group type: EXPERIMENTAL
Intervention: Buffered lidocaine
Number of subjects: 59
Study 7724308 — intervention group
Group type: COMPARATOR
Intervention: No analgesia
Number of subjects: 59
Study 1823965 — intervention group
Group type: COMPARATOR
Intervention: Induction therapy based on melphalan
Number of subjects: 208
Study 1823965 — intervention group
Group type: EXPERIMENTAL
Intervention: Polychemotherapy including vincristine, melphalan, carmustine, cyclophosphamide and prednisone
Number of subjects: 208
Study 1823965 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy supported by immunomodulatory agents (calf thymus extract, levamisole, interferon)
Number of subjects: 208
Study 1823965 — intervention group
Group type: EXPERIMENTAL
Intervention: Calf thymus extract
Number of subjects: 208
Study 1823965 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 208
Study 1823965 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon
Number of subjects: 208
Study 7036438 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (25 mg/kg over three days)
Number of subjects: 58
Study 7036438 — intervention group
Group type: COMPARATOR
Intervention: Fansidar (35 mg sulphadoxin (+ 1/20 pyrimethamine) per kg single dose)
Number of subjects: 58
Study 7036438 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine and Fansidar
Number of subjects: 58
Study 30982782 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure applied to acupuncture points (PC‐6, HT‐7, CV‐17), twice per day (2-4 sessions)
Number of subjects: 60
Study 30982782 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no pressure applied)
Number of subjects: 60
Study 26799154 — intervention group
Group type: EXPERIMENTAL
Intervention: Implant-assisted mandibular removable partial dentures
Number of subjects: 48
Study 26799154 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage 1 (healing caps)
Number of subjects: 48
Study 26799154 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage 2 (attachment system)
Number of subjects: 48
Study 26799154 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional mandibular partial dentures)
Number of subjects: 48
Study 25760153 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Periodization (TP)
Number of subjects: 10
Study 25760153 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily Undulating Periodization (DUP)
Number of subjects: 10
Study 23390192 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA (1000 mg EPA:200 mg DHA)
Number of subjects: 94
Study 23390192 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA (200 mg EPA:1000 mg DHA)
Number of subjects: 94
Study 23390192 — intervention group
Group type: COMPARATOR
Intervention: EPA
Number of subjects: 94
Study 23390192 — intervention group
Group type: COMPARATOR
Intervention: DHA
Number of subjects: 94
Study 22353416 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium Hydroxide + Ankaferd Blood Stopper (CH+ABS)
Number of subjects: 40
Study 22353416 — intervention group
Group type: COMPARATOR
Intervention: Calcium Hydroxide (CH)
Number of subjects: 40
Study 19379993 — intervention group
Group type: EXPERIMENTAL
Intervention: Miniaturized extracorporeal circulation
Number of subjects: 60
Study 19379993 — intervention group
Group type: COMPARATOR
Intervention: Off-pump coronary artery bypass grafting
Number of subjects: 60
Study 16924018 — intervention group
Group type: EXPERIMENTAL
Intervention: 14‐3‐3 protein
Number of subjects: 1859
Study 16924018 — intervention group
Group type: EXPERIMENTAL
Intervention: Tau protein
Number of subjects: 1859
Study 16924018 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined determination of 14‐3‐3 and Tau, S100b, or NSE
Number of subjects: 1859
Study 16924018 — intervention group
Group type: EXPERIMENTAL
Intervention: Second lumbar puncture
Number of subjects: 1859
Study 12716332 — intervention group
Group type: EXPERIMENTAL
Intervention: Powered toothbrush (PTB) with brushing force of 75 g for 30, 60, 120, and 180 seconds
Number of subjects: 12
Study 12716332 — intervention group
Group type: EXPERIMENTAL
Intervention: Powered toothbrush (PTB) with brushing force of 150 g for 30, 60, 120, and 180 seconds
Number of subjects: 12
Study 12716332 — intervention group
Group type: EXPERIMENTAL
Intervention: Powered toothbrush (PTB) with brushing force of 225 g for 30, 60, 120, and 180 seconds
Number of subjects: 12
Study 12716332 — intervention group
Group type: EXPERIMENTAL
Intervention: Powered toothbrush (PTB) with brushing force of 300 g for 30, 60, 120, and 180 seconds
Number of subjects: 12
Study 12716332 — intervention group
Group type: EXPERIMENTAL
Intervention: Brushing time of 120 seconds with forces in excess of 150 g
Number of subjects: 12
Study 12716332 — intervention group
Group type: EXPERIMENTAL
Intervention: Brushing time of 30, 60, 120, and 180 seconds with varying forces
Number of subjects: 12
Study 10938215 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine patch (used for the first 35 days)
Number of subjects: 27
Study 10938215 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine patch (removed after 35 days)
Number of subjects: 27
Study 10938215 — intervention group
Group type: COMPARATOR
Intervention: Control (nonsmokers)
Number of subjects: 27
Study 10938215 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine patch (for females)
Number of subjects: 27
Study 8828742 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral treatment
Number of subjects: 10
Study 8828742 — intervention group
Group type: COMPARATOR
Intervention: Control (1 patient)
Number of subjects: 10
Study 1345900 — intervention group
Group type: EXPERIMENTAL
Intervention: Broxaterol (0.5 mg three times a day for seven days)
Number of subjects: 16
Study 1345900 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 6369694 — intervention group
Group type: EXPERIMENTAL
Intervention: DTIC alone
Number of subjects: 196
Study 6369694 — intervention group
Group type: EXPERIMENTAL
Intervention: DTIC + bacillus Calmette‐Guérin
Number of subjects: 196
Study 6369694 — intervention group
Group type: EXPERIMENTAL
Intervention: DTIC + Corynebacterium parvum
Number of subjects: 196
Study 6369694 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (all treatments)
Number of subjects: 196
Study 6369694 — intervention group
Group type: EXPERIMENTAL
Intervention: Responders
Number of subjects: 196
Study 6369694 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with brain metastases
Number of subjects: 196
Study 6369694 — intervention group
Group type: EXPERIMENTAL
Intervention: Toxic effects
Number of subjects: 196
Study 29368539 — intervention group
Group type: EXPERIMENTAL
Intervention: ADS-5102 (amantadine) 274 mg once daily at bedtime
Number of subjects: 60
Study 29368539 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 28100469 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (20 mg/d)
Number of subjects: 2471
Study 28100469 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2471
Study 25962889 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised, facility-based exercise arm
Number of subjects: 240
Study 25962889 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise arm
Number of subjects: 240
Study 25962889 — intervention group
Group type: COMPARATOR
Intervention: Control group (maintains physical activity levels)
Number of subjects: 240
Study 23788694 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual cognitive-behavioral therapy (CBT)
Number of subjects: 168
Study 23788694 — intervention group
Group type: EXPERIMENTAL
Intervention: Group cognitive-behavioral therapy (CBT)
Number of subjects: 168
Study 23788694 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 168
Study 21291444 — intervention group
Group type: EXPERIMENTAL
Intervention: KiVa antibullying program
Number of subjects: 8237
Study 21291444 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 8237
Study 19849996 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal trivalent inactivated seasonal influenza vaccine (15 microg of haemagglutinin per strain per 0.1 ml dose)
Number of subjects: 3707
Study 19849996 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal trivalent inactivated seasonal influenza vaccine
Number of subjects: 3707
Study 19849996 — intervention group
Group type: COMPARATOR
Intervention: Conventional intramuscular vaccine
Number of subjects: 3707
Study 19849996 — intervention group
Group type: EXPERIMENTAL
Intervention: Both vaccines
Number of subjects: 3707
Study 16452696 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based representative payeeship coordinated with psychiatric care
Number of subjects: 184
Study 16452696 — intervention group
Group type: COMPARATOR
Intervention: Customary clinical care
Number of subjects: 184
Study 15315995 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine with CBT (10 to 40 mg/d)
Number of subjects: 439
Study 15315995 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine alone (10 to 40 mg/d)
Number of subjects: 439
Study 15315995 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT alone
Number of subjects: 439
Study 15315995 — intervention group
Group type: COMPARATOR
Intervention: Placebo (equivalent to 10 to 40 mg/d)
Number of subjects: 439
Study 15315995 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine with CBT
Number of subjects: 439
Study 11699608 — intervention group
Group type: EXPERIMENTAL
Intervention: E 5 mg (intranasal)
Number of subjects: 16
Study 11699608 — intervention group
Group type: EXPERIMENTAL
Intervention: E 10 mg (intranasal)
Number of subjects: 16
Study 11699608 — intervention group
Group type: EXPERIMENTAL
Intervention: E 50 mg (oral)
Number of subjects: 16
Study 11699608 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 9814459 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized regimen of calcium supplements and phosphorus binders, no vitamin D derivatives
Number of subjects: 52
Study 7640329 — intervention group
Group type: EXPERIMENTAL
Intervention: m-CPP (0.1 mg/kg) in untreated conditions
Number of subjects: 36
Study 7640329 — intervention group
Group type: EXPERIMENTAL
Intervention: Light treatment
Number of subjects: 36
Study 7640329 — intervention group
Group type: COMPARATOR
Intervention: m-CPP in untreated winter subjects
Number of subjects: 36
Study 7640329 — intervention group
Group type: COMPARATOR
Intervention: m-CPP in summer subjects
Number of subjects: 36
Study 2752859 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative irradiation (4000 cGy for 4 weeks) plus surgery
Number of subjects: 68
Study 2752859 — intervention group
Group type: COMPARATOR
Intervention: Surgical treatment without preoperative measures
Number of subjects: 68
Study 2752859 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative irradiation (4000 cGy for 4 weeks)
Number of subjects: 68
Study 593989 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of indomethacin
Number of subjects: 0
Study 593989 — intervention group
Group type: COMPARATOR
Intervention: Ultraviolet B (u.v.‐B) irradiation
Number of subjects: 0
Study 31831599 — intervention group
Group type: EXPERIMENTAL
Intervention: SAIL technique
Number of subjects: 110
Study 31831599 — intervention group
Group type: COMPARATOR
Intervention: ICL technique
Number of subjects: 110
Study 31507219 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-P6 (trastuzumab-pkrb, Herzuma)
Number of subjects: 0
Study 31507219 — intervention group
Group type: COMPARATOR
Intervention: Trastuzumab
Number of subjects: 0
Study 31507219 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-P6
Number of subjects: 0
Study 29196479 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital cognitive-behavioural therapy for insomnia (CBT-I) for 6 weeks
Number of subjects: 240
Study 29196479 — intervention group
Group type: COMPARATOR
Intervention: Online puzzle activity for 6 weeks
Number of subjects: 240
Study 26485217 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (50,000 IU orally once weekly for 8 weeks)
Number of subjects: 68
Study 26485217 — intervention group
Group type: COMPARATOR
Intervention: Placebo (oral placebo once weekly for 8 weeks)
Number of subjects: 68
Study 22576822 — intervention group
Group type: EXPERIMENTAL
Intervention: Video clips advance organizers (AO)
Number of subjects: 141
Study 22576822 — intervention group
Group type: EXPERIMENTAL
Intervention: Prosection advance organizers (AO)
Number of subjects: 141
Study 22576822 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 141
Study 21741720 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent re‐irradiation, fluorouracil and hydroxyurea (R‐RT)
Number of subjects: 57
Study 21741720 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (Ch‐T)
Number of subjects: 57
Study 19591339 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate Total toothpaste with triclosan
Number of subjects: 1357
Study 19591339 — intervention group
Group type: COMPARATOR
Intervention: Colgate sodium fluoride toothpaste without triclosan
Number of subjects: 1357
Study 16998133 — intervention group
Group type: EXPERIMENTAL
Intervention: School dental screening (3 different models)
Number of subjects: 16864
Study 16998133 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 16864
Study 12881261 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyoscine hydrobromide
Number of subjects: 107
Study 12881261 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrronium bromide
Number of subjects: 107
Study 12881261 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 107
Study 10838988 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Nurse Specialists (CNSs) present on units
Number of subjects: 0
Study 10838988 — intervention group
Group type: COMPARATOR
Intervention: No Clinical Nurse Specialists (CNSs) on units
Number of subjects: 0
Study 7475425 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 2012354 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin plus loperamide (4 mg first dose, 2 mg for every loose stool, max 16 mg/d)
Number of subjects: 104
Study 2012354 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin alone (placebo)
Number of subjects: 104
Study 2012354 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin plus loperamide
Number of subjects: 104
Study 7032948 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholestyramine/alginates/bicarbonate (CAB)
Number of subjects: 32
Study 7032948 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 2994512 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane anaesthesia
Number of subjects: 0
Study 2994512 — intervention group
Group type: COMPARATOR
Intervention: Epidural analgesia
Number of subjects: 0
Study 29499208 — intervention group
Group type: EXPERIMENTAL
Intervention: Water vapor thermal therapy (Rezūm® System)
Number of subjects: 1140
Study 29499208 — intervention group
Group type: COMPARATOR
Intervention: Any medical therapy (doxazosin and/or finasteride)
Number of subjects: 1140
Study 27085561 — intervention group
Group type: EXPERIMENTAL
Intervention: Music (n = 20)
Number of subjects: 40
Study 27085561 — intervention group
Group type: COMPARATOR
Intervention: Non-music (n = 20)
Number of subjects: 40
Study 24225048 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-activation potentiation (PAP) with 3 × 3-second maximal isometric squats
Number of subjects: 0
Study 24225048 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-activation potentiation (PAP)
Number of subjects: 0
Study 24225048 — intervention group
Group type: COMPARATOR
Intervention: Control protocol (without PAP)
Number of subjects: 0
Study 22967972 — intervention group
Group type: EXPERIMENTAL
Intervention: Narcotrend monitor
Number of subjects: 80
Study 22967972 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine method)
Number of subjects: 80
Study 20088735 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (docosahexaenoic acid and eicosapentaenoic acid) supplementation
Number of subjects: 0
Study 20088735 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 19087695 — intervention group
Group type: EXPERIMENTAL
Intervention: Yunnan Baiyao capsules, orally 4 days before operation once daily and then via nasal feeding tube after operation once a day for 5 days
Number of subjects: 87
Study 19087695 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 87
Study 16153398 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg mosapride (3 times daily for 5 days)
Number of subjects: 12
Study 16153398 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 16153398 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (2 mg administered after morphine)
Number of subjects: 12
Study 16153398 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 12
Study 16153398 — intervention group
Group type: EXPERIMENTAL
Intervention: Mosapride in rats (100 mg/kg orally)
Number of subjects: 12
Study 16153398 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone in rats
Number of subjects: 12
Study 12057728 — intervention group
Group type: EXPERIMENTAL
Intervention: Removal of necrotic blastomeres from frozen‐thawed human embryos
Number of subjects: 235
Study 12057728 — intervention group
Group type: COMPARATOR
Intervention: Control group (necrotic blastomeres not removed)
Number of subjects: 235